357 Long-term survivors after hormonotherapy (HT) in metastatic breast cancer (MBC). A retrospective study

• Published in: European journal of cancer (1990) 1995-11, Vol.31, p.S77-S78
• Main Authors: Esteban, B., Arranz, F.A., Alija, V., López, C., Erustes, M., Feyjoo, M., López, P., Alonso, A., Pérez Manga, G.
• Format: Article
• Language: English
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)95610-I

From a data base of 1724 patients (p) with MBC, we have analyzed a group of 436 p (25.3%) treated with HT as single first-line treatment. Patients who received simultaneous local therapy or chemotherapy were excluded. Treatment was elected according to clinical criteria. Mean age was 57 years (26–88), 429 p (98.4%) were female and 50% underwent adjuvant treatment of the primary tumor (median disease free interval: 24 months (m), range 0–276). Eighty-three percent (356 p) had suppressed ovarian function at the time of metastatic disease. One single metastatic site was seen in 66% of p. Metastatic sites were: bone (54%), skin (32%), lymph nodes (27%), lung (20%), pleura (7%), liver (2%) and other sites (I %). All p were evaluable for response. Overall response (OR): 151 p (34.7%), Complete Response (CR): 57 p (13.1%), No Changes (NC): 116 p (26.6%), and Progressive Disease (PD): 169 p (38.8%). At the end of the study, 28 of the 57 p (49%) remained in CR, after a median follow-up for response of 10 m (2–153). The median CR duration was 73 m (95% CI: 50–96). After a median follow-up for survival of 21 m (2–216),248 p (56%) have died. Median overall survival (and 95% CI) was 36 m (31–41) for the whole series, 128 m (86–170) for CR; 39 m (35–43) for PR, 46 m (39–53) for NC and 14 m (12–16) for PD. Differences in survival with statistical significance were found between CR vs PR, CR vs NC, CR vs PD, PR vs PD and NC vs PD. We conclude that long disease-free and overall survival can be seen in selected patients who obtain CR after HT as first line therapy.